

**The death mechanism of  
cardiomyocytes  
by hypoxic stress and the role of  
heat shock proteins**

**Bo Hee Shin**

**Department of Medical Science  
The Graduate School, Yonsei University**

**The death mechanism of  
cardiomyocytes  
by hypoxic stress and the role of  
heat shock proteins**

**Bo Hee Shin**

**Department of Medical Science  
The Graduate School, Yonsei University**

**The death mechanism of  
cardiomyocytes  
by hypoxic stress and the role of  
heat shock proteins**

Directed by Professor Yangsoo Jang

The Master's Thesis submitted to the  
Department of Medical Science,  
the Graduate School of Yonsei University  
in partial fulfillment of the requirements for the  
degree of Master of Medical Science

**Bo Hee Shin**

**December 2004**

**This certifies that the Master's  
thesis of Bo Hee Shin is approved.**

---

Yangsoo Jang : Thesis Supervisor

---

Jong Eun Lee : Committee Member

---

Ji Hyung Chung : Committee Member

**The Graduate School  
Yonsei University**

**December 2004**

## Acknowledgments

I thank many professors, colleagues, friends, and my family for their critical comments, supports and love. This thesis is the result of the dedicated effort of them.

I would like to thank Dr. Yangsoo Jang, Dr. Jong Eun Lee for insightful discussion of the manuscript and appreciate Dr. Ji Hyung Chung for his support, guidance and encouragement.

I wish to acknowledge Dr. Hyun Young Park, Dr. Kwang-Hoe Chung and Dr. Ki-Chul Hwang for their supports. I would like to thank those colleagues who have worked with Cardiovascular Research Center of Yonsei University, College of Medicine. Dr. Young-Doug Sohn, Dr. Hyun Joung Lim, Dr. Sung-Yu Hong, Dr. Hee-Sang Song, ZhengZhe Xu, Sae Hyung Lee, Jin Hong Lian, Woochul Chang and HunSu Chu.

I also thank Eun Kyoung Im, Jun Hye Kwon, Hye-Jin Shin, Bong Jun Cho, Eric J. C. Oh and Sook Kyung Lee for their encouragement.

I really appreciate my friends who have shared everything in Cardiovascular Research Center : Kyung Hye Lee, Eui Suk Hwang, Soo Jung Kang, So Yeon Lim, Sang Hyun Jee , Jin Woo Im, Sae Ah Sun, Hee Jin Sung and Sun Ju Lee.

I would like to express my gratitude and appreciation to my best friends YeongGyeong Jee and Sun Hye Kim. Their attention and affectionate comments have been very helpful to me.

Finally, I would like to say sorry to my family prior to say appreciation. If it had not been for their understanding and sacrifice, I could not have finished this thesis. I wish to thank my parents and my two brothers (Su-Yong and Yong-Ik) for their love.

I really thank my Lord who is always with me for everything.

December, 2004

Bo Hee Shin

# TABLE OF CONTENTS

<b>ABSTRACT</b> .....	1
<b>I. INTRODUCTION</b> .....	4
<b>II. MATERIALS AND METHODS</b> .....	10
1. Materials .....	10
2. Animals .....	10
3. Cell culture .....	11
4. Cell treatment and experimental hypoxia .....	12
5. Troponin I staining .....	12
6. Propidium Iodide staining .....	13
7. DNA fragmentation .....	13
8. MTT assay .....	14
9. Caspase-3 activity assay .....	15
10. Immunoblot analysis .....	16
11. Gene construction and protein purification of HSP70-TAT .....	17
<b>III. RESULTS</b> .....	19
1. Confirmation of primary cultured rat cardiomyocytes ...	19

2. Cell death by hypoxia insult with serum deprivation in cardiomyocytes .....	21
3. Expression of HSPs under hypoxic condition .....	26
4. MAPKs and MKP-1 expression in hypoxia .....	28
5. MAPKs and MKP-1 is regulated by HSP70 .....	30
6. HSP70 transduction into cells and activation of ERK ...	35
7. MKP-1 inactivates ERK.....	38
8. MKP-1 inhibition increases caspase-3 activity .....	40
<b>IV. DISCUSSION</b> .....	42
<b>V. CONCLUSION</b> .....	46
<b>REFERENCES</b> .....	47
<b>ABSTRACT (in Korean)</b> .....	58

## LIST OF FIGURES

Figure 1. The morphological character of neonatal rat cardiomyocytes....	20
Figure 2. Viability and caspase-3 activity of neonatal rat cardiomyocytes incubated under hypoxia with different serum concentration. ....	24
Figure 3. Hypoxia-induced apoptosis in cardiomyocytes. ....	25
Figure 4. The expression of heat shock proteins in cardiomyocytes under hypoxic condition. ....	27
Figure 5. Phosphorylation of MAPKs and expression of MKP-1 under hypoxic condition. ....	29
Figure 6. Effect of HSP70 inhibitor on MAPKs phosphorylation in cardiomyocytes under hypoxia. ....	32
Figure 7. Effect of HSP70 inhibitor on the expression of MKP-1 under hypoxia. ....	33
Figure 8. Effect of MKP-1 inhibitor on the HSP70 induction under hypoxia.	



.....	34
Figure 9. Construction and purification of TAT-HSP70.....	36
Figure 10. TAT-HSP70 transduction into cardiomyocytes and its effect on the ERK activation and MKP-1 expression under hypoxia .....	37
Figure 11. Effect of MKP-1 inhibitor on the activation of MAPKs under hypoxic condition .....	39
Figure 12. Effect of HSP70 and MKP-1 on the caspase-3 activity in cardiomyocytes under hypoxia. ....	41

## **LIST OF ABBREVIATIONS**

HSP : heat shock protein

MAPK : mitogen-activated protein kinase

MKP-1 : mitogen-activated protein kinase phosphatase-1

ERK : extracellular signal-regulated kinase

JNK : c-jun N-terminal kinase

HPX : hypoxia

NMX : normoxia

SD : serum deprivation

HSP-IH : Heat shock protein 70 inhibitor-1

**Abstract**

**The death mechanism of cardiomyocytes by hypoxic stress  
and the role of heat shock proteins**

**Bo Hee Shin**

*Department of Medical Science*

*The Graduate School, Yonsei University*

**(Directed by Professor Yangsoo Jang)**

Ischemia/hypoxia is a major factor of cardiovascular diseases, which are generated from apoptotic cells. Many studies have suggested that the mitogen-activated protein kinases (MAPKs) as well as heat shock proteins (HSPs) may be important regulators of apoptosis in response to hypoxia stress in cardiomyocytes. However, the precise mechanisms involved in stress recognition and progression to apoptosis in response to hypoxia or serum

deprivation remains largely uncertain. Here we investigated the cell death mechanisms of cardiomyocytes and the involvement of HSP70, MKP-1 and ERK under hypoxia. Neonatal rat cardiomyocytes exposed to simulated hypoxia were used as an *in vitro* model to delineate the roles of HSP70, MAPKs, as well as MKP-1 in apoptosis. Exposure of the cardiomyocytes to hypoxia with serum deprivation reduced cell viability, as measured by the MTT assay, and stimulated apoptosis as evidenced by caspase-3 activation and DNA fragmentation. Under hypoxia condition, serum deprivation is required to complete the apoptotic pathway in cardiomyocytes. Hypoxia insult resulted in an inactivation of ERK, while MKP-1 expression was increased at early time. Induction of HSP70 also increased shortly after the onset of hypoxia. Under hypoxia condition, interestingly, inhibition of HSP70 significantly increased the MKP-1 expression and caspase-3 activity, on the other hand, ERK phosphorylation was reduced more than only hypoxic group. Cardiomyocytes pretreated with vanadate, a MKP-1 inhibitor, showed a significant increase in ERK phosphorylation and attenuation of the caspase-3 activity under hypoxia. To confirm the roles of HSP70 under hypoxia, recombinant HSP70 protein fused with a protein transduction domain TAT was transduced into cardiomyocytes. After HSP70 transduction into cardiomyocytes, MKP-1 expression was significantly reduced under hypoxic

condition whereas ERK phosphorylation was recovered. Our results suggest that HSP70 has a protective role while MKP-1 expression is proapoptotic in cardiomyocytes under hypoxia and that these proteins are correlated precisely with ERK activity.

---

Key words : Cardiomyocytes, HSP70, MKP-1, ERK, Hypoxia, and Apoptosis.

**The death mechanism of cardiomyocytes by hypoxic stress  
and the role of heat shock proteins**

**Bo Hee Shin**

*Department of Medical Science*

*The Graduate School, Yonsei University*

**(Directed by Professor Yangsoo Jang)**

**I. INTRODUCTION**

The function of apoptosis in regulating cardiovascular diseases has recently been extensively investigated as a possible mechanism explaining the pathophysiological significance <sup>1,2</sup>. It is known that cellular apoptosis is associated with cardiovascular diseases such as myocardial infarction <sup>3</sup> and reperfusion <sup>4</sup>, heart failure <sup>5</sup>, diabetes <sup>6</sup>, cardiac hypertrophy <sup>7</sup> and left ventricular remodeling <sup>8</sup>. Recent studies have focused on the signaling events that influence this cardiac cell death <sup>1,9,10</sup>. Recent reports have also supported

that cellular apoptosis derives to death of cardiomyocytes in response to a range of stresses such as hypoxia <sup>11</sup>, free radical stress <sup>12</sup>, adrenergic over stimulation <sup>13</sup> and viral infection <sup>14</sup>.

Heat shock proteins (HSPs) are induced in response to stresses caused by agents, such as high temperature, hypoxia/ischemia, oxidative stress and pressure overload <sup>15</sup>. HSPs are highly conserved molecules that fulfill a range of functions, including cytoprotection, intracellular assembly, folding and translocation of oligomeric proteins <sup>16</sup>. These proteins are induced in most of mammalian cells and categorized into several families that are named on the basis of their approximate molecular weight (e.g. HSP90, HSP70, HSP60 and HSP27). Transcription of HSP gene is regulated by heat shock factors (HSFs), which form homotrimers under various stress conditions; these then move to the nucleus where they bind to a specific heat shock element (HSE) within the promoter region of the HSP gene <sup>17,18</sup>. The stress response is only transient, because a prolonged and inappropriate presence of protein-binding molecules would adversely influence protein homeostasis and a variety of intracellular functions. Especially, it is well established that HSPs are induced in response to hypoxia and may act as important regulators against cardiac cell apoptosis <sup>2,19</sup>. Two HSPs, the strongly stress-induced HSP70 and HSP27 are the best-studied members of the HSP family in human cells. Upregulation of these

proteins can be cytoprotective and can increase the survival of cells exposed to hypoxia known as an inducer of apoptosis<sup>20</sup>.

Pathophysiological hypoxia stress causes cells to lose viability. Hypoxia is also an important factor of apoptotic cell death<sup>21</sup> and gene expressions in cardiomyocytes. Hypoxic stress also activates a variety of signaling pathways such as the cAMP-protein kinase A (PKA)<sup>22</sup>, p42/44 mitogen-activated protein kinase (MAPK)<sup>23</sup>, stress-activated protein kinase (SAPK; p38 kinase)<sup>24</sup> and phosphatidylinositol 3-kinase/Akt<sup>25</sup>, leading to different cellular events in several cell types. In cardiac myocytes, MAPK pathways have been known as important downstream transducers of hypoxia/ischemia stimuli. Three major members of the MAPK family, ERK1/2, JNK1/2 and p38 MAPK, are involved in the regulation of a large variety of cellular processes such as cell growth, death and survival. ERK1/2 activation is observed during ischemia/hypoxia in heart and plays an important role in prevention of cardiac myocytes apoptosis, both in cultured cardiomyocytes and in the intact heart<sup>26,27</sup>. The p38 MAPK pathway belongs to the most investigated, but also the most controversial signaling pathway in cardiac responses to hypoxic insult. It has been reported that activation of p38 during ischemia/hypoxia is shown to be involved in proapoptotic signals<sup>26</sup>. In contrast, others showed that p38 activation during a short preconditioning treatment protects cardiomyocytes



from ischemic cell death <sup>28</sup>, suggesting a protective role of p38-MAPK activation during ischemia. In some studies, it was found that p38 MAPK mediated cytoprotection through phosphorylation of the small heat shock protein  $\alpha\beta$ -crystallin <sup>29</sup>, and through activation of NF- $\kappa$ B and subsequent release of anti-apoptotic cytokines <sup>30</sup>. Whether p38 acts as a cytoprotective or proapoptotic agent is likely to depend on both the intensity and the duration of p38 MAPK activation. Some studies also documented the possible role of another MAP kinase pathway, JNK, in cardiac apoptosis. JNK activation correlates with many cell lines including cardiac myocytes apoptosis in response to mechanical stress <sup>31</sup>, cytokines <sup>32</sup>, and oxidative stress <sup>27,33</sup>; however, the precise role of JNK in apoptosis and pathophysiology of ischemia/hypoxia stress remains unresolved.

MAPKs are regulated by MAPK phosphatase-1 (MKP-1) that has dual catalytic activity toward phosphotyrosine- and phosphothreonine-containing proteins, and is known to inactivate ERKs and JNKs <sup>34,35</sup>. The MKPs play a major role in regulating the activity of MAPKs. MKP-1 is transcribed as an immediate early response gene following various stimuli <sup>36-38</sup>, but its role in the cardiomyocytes is poorly understood. Recently, a few studies have addressed the role of MKP-1 in cardiac growth and hypertrophic response <sup>39</sup>. Transgenic mice expressing physiological levels of MKP-1 in the heart

showed no activation of p38, JNK1/2, or ERK1/2; diminished developmental myocardial growth; and attenuated hypertrophy in response to aortic banding and catecholamine infusion <sup>39</sup>. Nowadays, it has been studied that MKP-1 regulates MAPKs by HSP70 under heat stress <sup>34</sup>. HSP70 suppressed ERK activation by both protecting dual-specificity phosphatases, which was independent of the chaperone activity <sup>34</sup>. HSP70 can also inhibit JNK activation induced by a number of stresses, including heat shock <sup>40</sup>, ethanol <sup>41</sup>, and ultraviolet (UV) irradiation <sup>42</sup>. In addition, it has been suggested that HSP70 modulates JNK activity via inhibition of its dephosphorylation <sup>34,43</sup>

We investigated here the cell death mechanisms of cardiomyocytes and the involvement of HSP70, MKP-1 and ERK under hypoxia. We make *in vitro* apoptotic condition with controlling serum deprivation in hypoxia condition. In this condition, hypoxia stress transiently induced HSP70 in cardiomyocytes, and concurrently induced MKP-1 expression. This transient induction of HSP70 and MKP-1 influenced the activation of MAPKs. The MAPKs were inactivated at early time of hypoxic condition in cardiomyocytes. Especially, pretreatment of a MKP-1 inhibitor, vanadate, significantly recovered the ERK1/2 phosphorylation under the hypoxic condition. Interestingly, when cardiomyocytes was treated with HSP70 inhibitor, MKP-1 expression level was significantly increased whereas ERK1/2 phosphorylation was reduced.

Our results indicate that expression of MKP-1 by hypoxic stress to dephosphorylation of ERK1/2 is the initial event that commits the cardiomyocytes to the apoptotic pathway and it is regulated by HSP70. Hypoxia exposing of cardiomyocytes triggers numerous signaling events, which contribute to either cell death or survival. This study suggests that the HSP70 signal pathway plays an important role in the regulation of MKP-1 expression and ERK activation in hypoxia-induced cardiomyocytes death.

## **II. MATERIALS AND METHODS**

### **1. Materials**

Polyclonal heat shock protein (HSP70, 60, 27 and HSC70) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Also, anti-phospho-p38, phospho-JNK, phospho-ERK, p38, JNK and ERK were obtained from Santa Cruz Biotechnology. Monoclonal anti- $\beta$ -actin antibody was from Sigma (St. Louis, MO, USA). Horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence (ECL) Western blotting detection system were obtained from Santa Cruz Biotechnology, and Amersham Biosciences (Uppsala, Sweden), respectively. HSP inhibitor I was purchased from Calbiochem (San Diego, CA, USA). MKP-1 inhibitor (sodium orthovanadate) was obtained from Sigma (St. Louis, MO, USA). Caspase-family colorimetric substrate set plus for caspase-3 activity test was from BioVision, Inc (Mountain View, CA, USA).

### **2. Animals**

Neonatal Sprague-Dawley rat 1~2days old were used for this study. All animal procedures were carried out according to a protocol approved by the Yonsei University Animal Care Committee.

### **3. Cell culture**

Ventricular myocytes from the hearts of neonatal Sprague-Dawley rats (1~2 days old) were cultured according to the previously described methods with minor modifications<sup>44-46</sup>. The isolated heart tissues were washed with phosphate-buffered saline (PBS) in order to deplete red blood cell and minced. The minced myocardial tissues were incubated with 0.1% collagenase type II (Gibco BRL, Grand Island, NY, USA) with PBS at 37°C. The fresh 0.1% collagenase type II solution was added and the incubation procedure was repeated until the tissue was totally digested. The resulting supernatant was collected and equal volume of minimum Essential Medium Alpha Medium ( $\alpha$ -MEM, Gibco BRL) containing 10% fetal bovine serum (FBS) and 100U/ml penicillin/streptomycin (Gibco BRL) was added. Cell pellets were obtained by centrifugation. The cells resuspended in fresh medium containing 10% FBS were preplated in culture dish and incubated for at least 1hr at 37°C in 5% CO<sub>2</sub> incubator. The fibroblasts adhered to the dish surface, and the cardiomyocytes remained unattached. Unattached cardiomyocytes were replated on primary culture dish (Falcon, Bedford, MA, USA) and incubated in  $\alpha$ -MEM supplemented with 10% FBS. Cells were maintained in a 5% CO<sub>2</sub> incubator for 24hr, at which spontaneously contracting confluent cells were noted. In order to reduce fibroblast contamination, we used  $\alpha$ -MEM with

0.1mM 5-bromo-2 -deoxyuridine (Brd-U) (Sigma, St. Louis, MO, USA)

#### **4. Cell treatment and experimental hypoxia**

After overnight incubation, fresh serum-free or 10% serum contained medium were added. MAPK inhibitors were then added, and cells were returned to the incubator or placed in the hypoxia chamber. The airtight humidified chamber (Anaerobic Environment, ThermoForma, Marietta, OH, USA) which was maintained at 37°C and continuously gassed with a mixture of 10% CO<sub>2</sub>, 5% H<sub>2</sub> and 85% N<sub>2</sub> was used. For concurrent normoxic conditions, cells were placed in a Forma Scientific incubator gassed with 95% air, 5% CO<sub>2</sub> at 37°C.

#### **5. Troponin I staining**

Cardiac troponin I was identified on the cardiomyocytes. For assessment, the cardiomyocytes were cultured and incubated for 24hr and  $\alpha$ -MEM was discarded and rinsed by PBS. After then, cells were fixed by 50% acetone/50% methanol for 2min and rinsed by PBS. Second fixed was for 10min by H<sub>2</sub>O<sub>2</sub> and washed by PBS. Cardiomyocytes were incubated for 24hr with a 1:100 dilution of anti-cardiac troponin I antibody (Santa Cruz Biotechnology) at room temperature, washed by PBS with 1% triton X-100 for 5min and

followed by a 1:200 dilution of biotin-conjugated anti-mouse IgG antibody (DAKO, Carpinteria, CA, USA) for 30min and 1:200 dilution of horse-radish peroxidase conjugated streptavidine (DAKO, Glostrup, Denmark). Cells were washed by PBS for 5min and treated Large Volume DAB substrate system (Lab Vision Corporation, Fremont, CA, USA). These cardiomyocytes were carried out counter staining with Mayer's Hematoxyline and mounted.

## **6. Propidium iodide staining**

Primary cultured rat cardiomyocytes were plated in 4-well chamber slide and incubated for 24hr in 5% CO<sub>2</sub> incubator. The cells were washed and cultured with serum-free  $\alpha$ -MEM for 24hr, and accessed propidium iodide (PI) staining manner. The mediums were discarded, and cells were fixed with 1% paraformaldehyde for 5min. Second fixation was carried out by 70% ethanol for 1min. Fixed cardiomyocytes were washed with PBS and added 200ul of PBS. After then, PI (100ug/ml PBS) was treated on the cells. After 3min, the cells were observed by fluorescent microscope.

## **7. DNA fragmentation**

Cultured and hypoxia treated cardiomyocytes were gently homogenized in 0.5ml of DNA homogenization buffer, and transferred the homogenate to a

1.5ml tube. After adding 31.25ul 10% SDS, incubate at 65°C for 30min. 87.3ul of 8M potassium acetate (pH 8.0) were added. Mixture was incubated on ice for 1hr and obtained supernatant by centrifugation at 14,000rpm for 10min. The supernatant was added an equal volume of phenol : chloroform : isoamylalcohol (25:24:1), and transferred upper phase to new tube, and also added equal volume chloroform : isoamylalcohol (24:1). Transferred upper phase was stored overnight at -80°C with 2.5vol of cold 100% ethanol. Next day, sample was centrifuged and obtained as white pellet. The 1 X TE buffer and 2ul RNase (1ug/ml) were added, and the mixture was incubated at 37°C for 1hr. The phenol extraction step was repeated and upper phase was collected. Sample was treated with 0.1vol of 3M sodium acetate (pH 5.2) and 2.5vol of cold 100% ethanol, and incubated at -70°C for at least 1hr. After obtaining the pellet by centrifugation, sample was dried, resuspended with dH<sub>2</sub>O, and stored at -20°C. Finally, it was fractionated on a 1.5% agarose gel and stained with ethidium bromide.

## **8. MTT assay**

Cell viability was determined by the MTT assay. The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) (5mg/ml) was dissolved in PBS. Cells were plated in 4-well dish for 24hr. They were then



transferred to hypoxic chamber. After 6hr, 24hr or 48hr, culture medium was aspirated and 0.5ml of MTT solution was added. The plates were then replaced in the incubator. After 3hr, the MTT solution was aspirated and MTT/formazan was extracted with 0.5ml dimethylsulfoxide (DMSO) to dissolve. Optical densities at 570nm were measured using extraction buffer as a blank. Because MTT is metabolized to formazan by living, viable cells, a reduction of measured OD 570 compared to untreated healthy control cells indicates a loss of cell growth and viability.

#### **9. Caspase-3 activity assay.**

The activity of caspase-3 in the cardiomyocytes was determined spectrophotometrically with an Apoalert™ CPP32/caspase-3 assay kit (BD Science, Palo Alto, CA, USA) by measuring the release of the chromophore, pnitroanilide (*p*NA), following hydrolysis of DEVD-*p*NA. Primary cultured cardiomyocytes were incubated in  $\alpha$ -MEM with or without FBS. Samples were transferred to hypoxic condition and incubated for 24hr. After then, cells were harvested, resuspended in chilled cell lysis buffer and incubated on ice for 10min. Cells were centrifuged and supernatants were transferred to a fresh tube. Protein concentration was determined by the Bradford assay (Bio-Rad, Hercules, CA, USA). Equal amounts of protein in the lysates were incubated

with substrate. It was proper to diluted 100~300ug protein in 50ul cell lysis buffer for each assay. The 50ul of 2 X Reaction Buffer containing 10mM dithiothreitol (DTT) was added and each samples were incubated with 5ul of DEVD-*p*NA (4mM) at 37°C for 1hr. Caspase-3 activity was read in a microtiter plate reader at 405nm, and a standard curve was generated using as standard CPP32 chromogenic substrate.

## **10. Immunoblot analysis**

Primary cultured rat cardiomyocytes were treated for various experimental conditions with hypoxia. At the end of the various treatments, harvested cells were solubilized in a Cell Lysis Buffer (Cell signaling, Beverly, MA, USA) with 1mM PMSF for 15min at 4°C and the protein lysate concentrations were measured by Bradford protein assay kit (Bio-Rad). The same amounts of proteins from whole cell lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto methanol-treated PVDF membranes (Millipore Co, Bedford, MA, USA). After blocking the membrane with Tris-buffered saline-tween 20 (TBS-T, 0.1% tween 20) containing 5% skim milk (Bio-Rad) for 60min at room temperature, they were washed twice with TBS-T and incubated with primary antibodies for 1hr at room temperature or for overnight at 4°C. The

membranes were washed three times with TBS-T for 10min, and then incubated for 45min at room temperature with horseradish peroxidase (HRP)-conjugated secondary antibodies. After extensive washing, the bands were detected by enhanced chemiluminescence (ECL) reagent (Santa Cruz Biotechnology). The band intensities were quantified using Phospho-Image System (Molecular Dynamics, Uppsala, Sweden)

## **11. Gene construction and protein purification of HSP70-TAT**

TAT-beta-galactosidase (TAT-*-gal*) and the 6 X His-TAT cloning vector (pTAT-HA, where HA is hemagglutinin) were kindly provided by Dr. Steven Dowdy (Cancer Center, UCSD, USA). The pTAT-HA vector contains an ampicillin resistance marker for selection after transformation, a T7 polymerase promoter, an N-terminal 6-histidine leader before the TAT domain, and an HA tag. HSP70-TAT fusions were generated by insertion of the HSP70 open reading frame (ORF) DNA into the pTAT-HA plasmid. The HSP70 cDNA was removed from the pcDNA3.1-HSP70 plasmid by double digestion with *XhoI* and *EcoRI*. The HSP70 DNA was then ligated into the pTAT-HA vector by double digestion of the multiple cloning sites within pTAT-HA with *XhoI* and *EcoRI*. Plasmids were transformed into *E. coli* DH5 $\alpha$ . Individual clones were isolated and analyzed for the correct HSP70 by DNA sequencing.


The recombinant plasmid pTAT-HSP70 was introduced into *E. coli* strain BL21 (DE3). *E. coli* harboring pTAT-HSP70 was inoculated into LB media (1% tryptone, 0.5% yeast extract, and 0.5% NaCl) containing 50ug/ml of ampicillin to a density of A600 of 1.0 at 37°C. Recombinant proteins were induced with 0.5mM of isopropyl-b-D-thiogalactopyranoside (IPTG) at 30°C for 6hr. The cells were centrifuged at 6,000rpm for 20min, and then cell pellets were resuspended in buffer A (50mM NaH<sub>2</sub>PO<sub>4</sub>, 300mM NaCl, 6M urea, pH8.0). Cells were disrupted by ultrasonication and the lysates were centrifuged at 15,000rpm for 30min. The supernatant was applied to a Ni-NTA agarose resin column (Qiagen, Hilden, Germany) pre-equilibrated in buffer A at a flow rate of 1ml/min. The flow-through was discarded and proteins were washed with additional column volumes of buffer A 10 times. The TAT-HSP70 was eluted from the column with buffer B (50mM NaH<sub>2</sub>PO<sub>4</sub>, 300mM NaCl, 300mM imidazole, pH 8.0). The protein fractions were pooled and desalted into 1 ml PBS on PD-10 columns. The protein fractions were identified by 15% SDS-PAGE analysis.

### **III. RESULTS**

#### **1. Confirmation of primary cultured rat cardiomyocytes**

The mammalian heart is composed of many cell types. Approximately 75% of the cells are non-myocardial cells, such as fibroblasts and red blood cells. Myocardial cells, also known as cardiomyocytes, make up the remaining 25% of the cells in the organ. Despite their smaller numbers, cardiomyocyte make up the largest volume of the heart <sup>47</sup>. Common problem with cultured cardiomyocytes is contamination with fibroblasts. Because of these reasons, we first checked morphological characteristics of cardiomyocytes by microscopy (Fig. 1-A). Rhythmically contracting areas appeared at 1 day after plating. Using immunocytochemistry, the presence of cardiac-specific protein Troponin I and its spatial organization were also examined in contracting cells. Fig. 1-B shows positive immunostaining of dispersed cardiomyocytes with anti-cardiac Troponin I monoclonal antibody. It was shown that cardiomyocytes have a star-shaped profile. Therefore, we just used more than 90% pure cardiomyocytes in the following experiments.

**A**



**B**



**Figure 1. The morphological character of neonatal rat cardiomyocytes.** Neonatal rat cardiomyocytes were incubated in a CO<sub>2</sub> incubator at 37°C for 24hr. (A) Cardiomyocytes were observed by phase-contrast inverted microscope. Rhythmically contracting areas appeared at 1day after plating. (B) Cardiomyocytes were stained with anti-cardiac troponin I monoclonal antibody. It was shown that cardiomyocytes have a star-shaped profile.

## **2. Cell death by hypoxia insult with serum deprivation in cardiomyocytes**

Apoptosis and necrosis are two distinct forms of cell death. Nevertheless, there is increasing evidence that most cardiac diseases are related with apoptosis. In this reason, we decided to make apoptotic condition *in vitro*, in order to identify hypoxia-induced cardiomyocytes death. Many of studies have shown that hypoxia insult generates apoptotic cell death. However, we found that only hypoxia (*in vitro*) could not induce apoptotic death of cardiomyocytes in preliminary data <sup>48</sup>. Therefore, we made appropriate apoptotic condition by controlling serum concentration with hypoxia because the cardiomyocytes are very sensitive to serum concentration containing culture medium. The cardiomyocytes were treated in two experimental conditions, hypoxia with serum-deprived (SD) media or hypoxia with 10% serum-containing media, and then cell viability was determined by MTT assay (Fig. 2-A). It was shown that serum-deprived cardiomyocyte underwent cell death but the differences between hypoxia and normoxia were not observed within 24hr. In the presence of serum, hypoxia for up to 24hr did not induce significant cell death. The remarkable differences of cell viability between hypoxic group and normoxic group were shown after 48hr. The death rate of cardiomyocytes was increased in the combination group of hypoxia


and 10% serum more than serum-deprived group with hypoxia. These results suggest that serum in culture medium is an important factor to determine cell death pattern in cardiomyocytes. To further examine the contribution of serum to cardiomyocytes apoptosis under hypoxic condition, cardiomyocytes were subjected to hypoxia with different serum concentration (0, 0.5 or 10%) in culture medium for 24hr. The combination of hypoxia and serum deprivation significantly increased the level of caspase-3 activity (Fig.2-B). Under hypoxic condition, caspase-3 activities of cardiomyocytes in serum deprivation or 0.5% serum condition were increased about 4-folds and 8-folds, respectively. On the other hand, in the presence of 10% serum with hypoxia, caspase-3 activity level was increased by about 1.7-folds compared to control normoxia (Fig.2-B). These results indicate that caspase-3 activation by hypoxia depends on serum concentration in neonatal cardiomyocytes, and these cells are much more sensitive to serum deprivation than to hypoxia.

In order to determine the apoptotic effect of hypoxia with serum deprivation in cardiomyocytes, we examined the propidium iodide (PI) staining and DNA fragmentation. The PI-stained nuclei were shown in cardiomyocytes under normal condition (Fig. 3-A). Treatment with serum deprivation under hypoxia induced morphological changes (i.e. fragmentation of nucleus) consistent with apoptosis, whereas no apoptotic signal was shown in cardiomyocytes under




normoxia condition. Cultured cardiomyocytes exposed to hypoxia with serum deprivation for 24 h exhibited the typical apoptotic DNA fragmentation (Fig. 3-B). The 100bp DNA fragments were used as marker.

**A**




**B**




**Figure 2. Viability and caspase-3 activity of neonatal rat cardiomyocytes incubated under hypoxia with different serum concentration.** (A) Primary cardiomyocytes were incubated with or without 10% serum in a hypoxic chamber for the indicated time. Cell viability was assessed by the MTT assay. Data are average of three independent experiments. (B) Primary cardiomyocytes were incubated with different serum concentration in hypoxic chamber for 24hr. Caspase-3 activity was measured. Results are representative of three independent experiments. NMX, normoxia; HPX, hypoxia; SD, serum deprivation; 10% serum, 10% serum containing; IH, treatment of caspase-3 inhibitor.

**A**




**B**



**Figure 3. Hypoxia-induced apoptosis in cardiomyocytes.** Cultured cardiomyocytes were incubated with serum-free  $\alpha$ -MEM under hypoxic condition for 24hr. (A) Cardiomyocytes were stained with propidium iodide (PI). The arrows indicate PI-stained nuclei. (B) DNA fragmentation patterns under hypoxia. The 100bp DNA ladders were used as marker. NMX, normoxia; HPX, hypoxia.

### **3. Expression of HSPs under hypoxic condition**

The accumulation of HSPs in cardiac cells enhances myocardial resistance to hypoxia/ischemia injury<sup>49,50</sup> and HSP70 is synthesized in the myocardium<sup>52</sup> following transiently induced ischemia. To investigate whether expression of HSPs increases in cardiomyocytes under hypoxic stress, cultured cardiomyocytes were exposed to hypoxia for varying periods of time. Expression of HSP70 gradually increased after the onset of serum deprivation under hypoxic conditions for 6hr (Fig. 4). The levels of HSP60 and HSC70 (constitutive form of HSP70) remained unaffected.




**Figure 4. The expression of heat shock proteins in cardiomyocytes under hypoxic condition.** Primary cardiomyocytes were incubated in hypoxia chamber. At the indicated times, samples were harvested, lysed and immunoblotted with anti-HSP70, HSP60, and HSC70.


#### **4. MAPKs and MKP-1 expression in hypoxia**

To further investigate whether the death mechanism of cardiomyocytes by hypoxia was involved in MAPKs signaling, we primarily examined the effect of hypoxia on the activation of three MAPKs and the expression of one phosphatase MKP-1. Cardiomyocytes were treated with serum deprivation under hypoxia for various times, and then MAPKs were determined by immunoblot with phospho-specific antibodies. As shown in Fig. 5-A, the phosphorylations of ERK and JNK were significantly reduced at early time. Phosphorylation of p38 MAPK was slightly reduced. It has been known that the expression level of MKP-1 was also examined under same condition as it is correlated with regulation of MAPKs activation<sup>34,35</sup>. Interestingly, the expression of MKP-1 was induced at early time in cardiomyocytes in hypoxia (Fig.5-B). These results suggest that MAPKs may play an important role in cardiomyocytes death under hypoxia and their activations are regulated by MKP-1.

**A**



**B**



**Figure 5. Phosphorylation of MAPKs and expression of MKP-1 under hypoxic condition.** Primary cardiomyocytes were incubated in hypoxia chamber. At the indicated times, samples were harvested, and phosphorylation of MAPKs (A) and expression of MKP-1 (B) were determined by immunoblotting.


## **5. MAPKs and MKP-1 is regulated by HSP70**

Since HSP70 induction is simultaneous event with MAPKs inactivation and MKP-1 expression in early time of hypoxic insult, as shown in Fig. 4 and 5, we hypothesized that the crosstalk between HSP70 induction and MAPKs, MKP-1 under hypoxia would be important for regulation of cell death in cardiomyocytes. So the effect of HSP70 inhibitor was studied. Primary cultured cardiomyocytes were pretreated with HSP Inhibitor I (HSP70 inhibitor, final 1uM), and then incubated under hypoxia for 1hr. Interestingly, the phosphorylation patterns of MAPKs were changed (Fig. 6). The JNK phosphorylation was recovered by HSP70 inhibitor treatment whereas phosphorylations of p38 and ERK were decreased under inhibitor-treated condition compared with only hypoxic condition.


To delineate the effect of HSP70 on the MKP-1 expression under hypoxia, cardiomyocytes were pretreated with HSP70 inhibitor and harvested after hypoxia for 1hr, and then immunoblot was examined. MKP-1 expression was significantly increased against the HSP70 inhibitor treatment, indicating regulation of HSP70 on the MKP-1 expression (Fig. 7). We next examined whether MKP-1 expression affects the HSP70 induction. Cardiomyocytes were treated with 100uM vanadate (MKP-1 inhibitor) and subjected to hypoxia. As shown in Fig. 8, no significant changes of HSP70 protein level




were observed with vanadate. These data suggest that hypoxia-induced MKP-1 expression is regulated by HSP70 in cardiomyocytes, at least in part.



**Figure 6. Effect of HSP70 inhibitor on MAPKs phosphorylation in cardiomyocytes under hypoxia.** Cardiomyocytes were pretreated with 1uM HSP70 inhibitor for 1hr, and subjected to hypoxia for 1hr. Samples were harvested, and phosphorylation of MAPKs was determined by immunoblotting (A). Each signal was quantified by scanning densitometry (B).



**Figure 7. Effect of HSP70 inhibitor on the expression of MKP-1 under hypoxia.** Cardiomyocytes were pretreated with 1uM HSP70 inhibitor for 1hr, and subjected to hypoxia for 1hr. Samples were harvested, and MKP-1 level was determined by immunoblotting.



**Figure 8. Effect of MKP-1 inhibitor on the HSP70 induction under hypoxia.** Cardiomyocytes were pretreated with 100uM vanadate (MKP-1 inhibitor) for 1hr, and subjected to hypoxia for 1hr. Samples were harvested, and HSP70 level was determined by immunoblotting.


## **6. HSP70 transduction into cells and activation of ERK**

To confirm the role of HSP70 on the activation of ERK and MKP-1, we used the recombinant HSP70 protein fused with a protein transduction domain (PTD), TAT (Fig. 9). Protein transduction is a technology by which proteins can be directly transferred into cells and TAT is one of the most widely studied PTD<sup>52</sup>. Cardiomyocytes were pretreated with TAT-HSP70 fusion protein for 1hr and incubated in hypoxia by a time-course. The fusion protein was transduced into cardiomyocytes (Fig. 10-A). Because TAT-HSP70 is fusion protein with TAT, transduced fusion protein compared with endogenous HSP70 was shown as upper shift band in immunoblot. After TAT-HSP70 transduction into cardiomyocytes, MKP-1 expression was significantly reduced under hypoxic condition (Fig. 10-B). In addition, ERK activation was recovered. These suggest that HSP70 upregulates the activation of ERK pathway via the downregulation of MKP-1 expression, indicating a potential roles of these proteins in cardiomyocytes apoptosis under hypoxia.

**A**




**B**




**Figure 9. Construction and purification of TAT-HSP70.** (A) pTAT-HSP70 expression vector (B) Purification of TAT-HSP70 fusion protein over Ni-NTA resin. The crude lysate from a 1L culture was applied to the resin in the presence of 10mM imidazole, washed, and eluted with (a)100, (b)150, (c)200 and (d)300mM imidazole. Ten microliters of each fraction were resolved by SDS-PAGE and stained with Coomassie blue.

**A**



**B**




**Figure 10. TAT-HSP70 transduction into cardiomyocytes and its effect on the ERK activation and MKP-1 expression under hypoxia.** (A) After transduction of 1 $\mu$ M TAT-HSP70 into cardiomyocytes, immunoblot analysis was performed using anti-HSP70 antibody. (B) Cardiomyocytes were treated with 1 $\mu$ M TAT-HSP70 and subjected to hypoxia. At the indicated time, samples were harvested, and the levels of phospho-ERK and MKP-1 were determined by immunoblotting. CTL, control; HPX, hypoxia; TAT-HSP70. HSP70 fusion protein.

## **7. MKP-1 inactivates ERK**

Recently, it has been reported that MAPKs may be regulated by MKP-1 and other dual-specificity phosphatases<sup>34,35,38</sup>. To examine the potential role of MKP-1 on the activation of MAPKs under hypoxia condition, we measured the phosphorylation of three MAPKs in cardiomyocytes treated with MKP-1 inhibitor. The phospho-ERK levels showed a dramatic increase at 1hr after treatment with MKP-1 inhibitor under hypoxia, suggesting MKP-1 regulates the ERK activation in hypoxia (Fig. 11). However, neither p38 MAPK nor JNK were significantly affected by MKP-inhibitor. These results, therefore, suggest that the MKP-1 phosphatase is induced in cardiomyocytes under hypoxia, and that expression of this phosphatase specifically regulates ERK activation.






**Figure 11. Effect of MKP-1 inhibitor on the activation of MAPKs under hypoxic condition.** Cardiomyocytes were pretreated with 100uM vanadate for 1hr, and subjected to hypoxia for 1hr. Samples were harvested, and phosphorylation of MAPKs was determined by immunoblotting (A). Each signal was quantified by scanning densitometry (B).

### **8. MKP-1 inhibition increases caspase-3 activity**

To further confirm whether MKP-1 was really involved in apoptotic events, we examined the effect of MKP-1 inhibitor on the caspase-3 activity in cardiomyocytes under hypoxia. Surprisingly, MKP-1 inhibitor could significantly decrease the caspase-3 activity under hypoxia whereas HSP70 inhibitor increased it (Fig.12). These data suggest that MKP-1 can activate caspase-3 pathway following cell death in cardiomyocytes.



**Figure 12. Effect of HSP70 and MKP-1 on the caspase-3 activity in cardiomyocytes under hypoxia.** Primary cardiomyocytes were incubated with 100uM vanadate or 1uM HSP70 inhibitor for 1hr and subjected to hypoxia for 1hr. Caspase-3 activity was measured using Caspase-3 fluorescent assay kit.

#### IV. DISCUSSION

The present study showed that HSP70 protects cardiomyocytes from hypoxic insult by causing a sustained activation of ERK via inhibiting the expression of MKP-1 expression under hypoxic condition. Generally upregulation of HSP70 can be cytoprotective and can increase the survival of cells exposed to a wide range of lethal stimuli by decreasing apoptosis via the caspase cascade<sup>53</sup>. In mammalian cells, HSP70 interacts with several regulatory proteins such as transcription factors, and kinases, some of which are involved in apoptotic events<sup>54</sup>. Indeed, HSP70 binds to Apaf-1, thereby preventing the recruitment of procaspase-9 to the apoptosome<sup>55,56</sup>. In our data, it also appears to regulate ERK and MKP-1. Many studies have addressed the role of MAPK pathway against hypoxia in different cell types. The MAPK signaling cascade has been implicated as a regulator of cardiomyocyte apoptosis in vitro as well as in heart. However, considerable disagreement persists as to the functional effects attributed to these signaling, given that both pro- and anti-apoptotic regulatory roles have been reported<sup>26-28</sup>.

MKP-1 is also induced by various stresses and mitogenic. MKP-1 was originally identified based on its specificity toward the ERK, but MKP-1 is a general MAPK phosphatase that can also dephosphorylate JNK<sup>35</sup>. Indeed, the

ability of MKP-1 to inactivate JNK has been linked in some cells to inhibition of apoptosis caused by stimuli<sup>57,58</sup>. Because MKP-1 is a specific inhibitor of MAP kinases, it may be involved in defense mechanisms against stress-induced apoptosis in cells. However, our data showed that expression of MKP-1 is involved in the cellular apoptosis against hypoxia stress in cardiomyocytes. Furthermore, this study demonstrated that induction of HSP70 in response to hypoxia may play an antiapoptotic role via inhibiting MKP-1 expression, as far as we believe, for the first time. These data support the hypothesis that HSPs are involved in not only mitochondria-mediated caspase pathways but also MAPKs pathway in hypoxia-induced cell death events.

It is unclear whether MAPKs and MKPs directly affect mitochondria-mediated caspase pathways. However, recently it has been reported that JNK and MKP-1 is associated with regulation of mitochondrial pathways of apoptosis<sup>59</sup>. In this study, hypoxic insult significantly induced MKP-1 expression and ERK inactivation at early time in cardiomyocytes. In this time, caspase-3 activity was also increased. When cardiomyocytes were treated with MKP-1 inhibitor under hypoxia, ERK phosphorylation was recovered and caspase-3 activity was decreased. These results indicate that ERK and MKP-1 cascade can contribute the apoptotic process through caspase-3

pathway. Actually, it has been well known that MAPKs-related apoptosis links with NF- $\kappa$ B<sup>30,60</sup>. NF- $\kappa$ B is a pleiotropic transcription factor implicated in the regulation of diverse biological phenomena, including apoptosis, cell survival, cell growth, and the cellular responses to ischemia/hypoxia<sup>61,62</sup>. Many of signaling cascades activate NF- $\kappa$ B by activating the I $\kappa$ B kinase (IKK) complex a major component of the canonical pathway. These signaling interactions occur largely via signaling crosstalk involving the mitogen-activated protein kinase/extracellular signal regulated kinase kinases (MEKKs) that are components of MAPK signaling pathways<sup>63</sup>. Accordingly, we could assume that the roles of ERK on the neutralizing apoptosis or cell survival under lethal stress are correlated with crosstalk of NF- $\kappa$ B.

Although we have found that HSP70 regulates MKP-1 expression, their relationship is not clear. The level of MKP-1 expression was defined using HSP70 inhibitor and HSP70 protein transduction. But its activity was not shown. One possibility is that HSP70 interacts with some molecule which regulates transcription of MKP-1. MKP-1 is early response gene, and its transcription involves the synergistic action of multiple cis-acting elements in the proximal promoter. So HSP70 might directly bind to MKP-1 transcription factors or cis-acting elements. Another possibility is MKP-1 is regulated by direct interaction with HSP70. These mechanisms require further studies.

We now show MKP-1 expression is involved in hypoxia-induced cardiac cell death and this is correlated precisely with ERK1/2 activity. And MKP-1 expression is regulated by HSP70. Thus, this study suggests a molecular mechanism on the beneficial role of HSP70 in hypoxia-induced apoptotic cardiomyocytes.

## V. CONCLUSION

We have demonstrated that HSP70 exert modulatory effects at distinct points along the apoptosis of cardiomyocytes under hypoxia. Immunoblot analyses showed that hypoxia with serum deprivation induced expression of MKP-1 and HSP70. MKP-1 inhibition is associated with a significant decrease of caspase-3 activity and attenuation of apoptosis, while HSP70 inhibition caused an increase in caspase-3 activation and apoptosis during hypoxia. The inhibition of HSP70 also significantly enhanced the expression of MKP-1 by hypoxia. Consistently, transduction with HSP70 into cardiomyocytes under hypoxia suppressed MKP expression and recovered ERK phosphorylation. These results indicate that MKP-1 is proapoptotic during hypoxia stress, whereas HSP70 limits hypoxia-induced apoptosis through the inhibition of MKP-1 expression. Furthermore, induction of MKP-1 in hypoxic condition is regulated by the HSP70 and this correlated precisely with ERK activity.





## REFERENCES

1. Nanette HB, Peter A, Tatiana S, Webster KA. Molecular mechanisms of apoptosis in the cardiac myocyte. *Curr Opin Pharm* 2001; 1: 141-150.
2. Giovanna D, Michele S, Andrea M, Giuseppe F. Heat shock proteins and their role in heart injury. *Curr Opin Crit Care* 2002; 8: 411-416.
3. Chow AW, Segal OR, Davies DW, Peters NS. Mechanism of pacing-induced ventricular fibrillation in the infarcted human heart. *Circulation* 2004;110: 1725-1730.
4. Parsa CJ, Kim J, Riel RU, Pascal LS, Thompson RB, Petrofski JA, Matsumoto A, Stamler JS, Koch WJ. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. *J Biol Chem* 2004; 279: 20655-20662.
5. Chang J, Wei L, Otani T, Youker KA, Entman ML, Schwartz RJ. Inhibitory cardiac transcription factor, SRF-N, is generated by caspase-3 cleavage in human heart failure and attenuated by ventricular unloading. *Circulation* 2003; 108: 407-413.
6. Adeghate E. Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: a short review. *Mol Cell Biochem* 2004; 261: 187-191.

7. Van Empel VP, De Windt LJ. Myocyte hypertrophy and apoptosis: a balancing act. *Cardiovasc Res* 2004; 63: 487-499.
8. Bussani R, Abbate A, Biondi-Zoccai GG, Dobrina A, Leone AM, Camilot D, Di Marino MP, Baldi F, Silvestri F, Biasucci LM, Baldi A. Right ventricular dilatation after left ventricular acute myocardial infarction is predictive of extremely high peri-infarctual apoptosis at postmortem examination in humans. *J Clin Pathol.* 2003; 56: 672-676.
9. Catherine G, Ruben M, Afshin S. Losing heart: the role of apoptosis in heart disease – a novel therapeutic target? *FASEB J* 2002; 16: 135-146.
10. Denecker G, Vercaemmen D, Declercq W, Vandenabeele P. Apoptotic and necrotic cell death induced by death domain receptors. *Cell Mol Life Sci* 2001; 58: 356-370.
11. Fortuno MA, Ravassa S, Fortuno A, Zalba G, Diez J. Cardiomyocyte apoptotic cell death in arterial hypertension: mechanisms and potential management. *Hypertension* 2001; 38: 1406-1412.
12. Pollack M, Phaneuf S, Dirks A, Leeuwenburgh C. The role of apoptosis in the normal aging brain, skeletal muscle, and heart. *Ann N Y Acad Sci* 2002; 959: 93-107.
13. Vatner DE, Asai K, Iwase M, Ishikawa Y, Shannon RP, Homcy CJ, Vatner SF. Beta-adrenergic receptor-G protein-adenylyl cyclase signal

- transduction in the failing heart. *Am J Cardiol* 1999; 83: 80H-85H.
14. Clarke P, Tyler KL. Reovirus-induced apoptosis: A minireview. *Apoptosis* 2003; 8: 141-150.
  15. Amere SS, Peter C. Heat shock proteins in the regulation of apoptosis: new strategies in tumor therapy a comprehensive review. *Pharm Thera* 2004; 101: 227-257.
  16. Hightower LE. Heat shock, stress proteins, chaperones and proteotoxicity. *Cell* 1991; 66:191-197.
  17. Voellmy R. Transduction of the stress signal and mechanisms of transcriptional regulation of heat shock/stress protein gene expression in higher eukaryotes. *Crit Rev Eukaryotic Gene Expression* 1994; 4: 357-401.
  18. Morimoto RI, Kline MP, Bimston DN, Cotto JJ. The heat-shock response: regulation and function of heat-shock proteins and molecular chaperones. *Essays Biochem* 1997; 32: 17-29.
  19. Pockley AG. Heat shock proteins, inflammation, and cardiovascular disease. *Circulation* 2002; 105: 1012-1017.
  20. Brar BK, Stephanou A, Wagstaff MJ, Coffin RS, Marber MS, Engelmann G, Latchman DS. Heat shock proteins delivered with a virus vector can protect cardiac cells against apoptosis as well as against thermal or hypoxic stress. *J Mol Cell Cardiol* 1999; 31: 135-146.

21. Seta KA, Millhorn DE. Functional genomics approach to hypoxia signaling. *J Appl Physiol* 2004; 96: 765-773.
22. Beitner-Johnson D, Leibold J, Millhorn DE. Hypoxia regulates the cAMP-and Ca<sup>2+</sup>/calmodulin signaling systems in PC12 cells. *Biochem Biophys Res Commun* 1998; 241: 61-66.
23. Conrad PW, Freeman TL, Beitner-Johnson D, Millhorn DE. DPAS1 trans-activation during hypoxia requires p42/p44 MAPK. *J Biol Chem* 1999; 274: 33709-33713.
24. Conrad PW, Rust RT, Han J, Millhorn DE, Beitner-Johnson D. Selective activation of p38 alpha and p38 gamma by hypoxia. Role in regulation of cyclin D1 by hypoxia in PC12 cells. *J Biol Chem* 1999; 274: 23570-23576.
25. Beitner-Johnson D, Rust RT, Hsieh TC, Millhorn DE. Hypoxia activates Akt and induces phosphorylation of GSK-3 in PC12 cells. *Cell Signal* 2001; 13: 23-27.
26. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greengard ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. *Science* 1995; 80: 1326-1331.
27. Yue TL, Wang C, Gu JL, Ma XL, Kumar S, Lee JC, Feuerstein GZ, Thomas H, Maleeff B, Ohlstein EH. Inhibition of extracellular signal-regulated kinase enhances ischemia/reoxygenation-induced apoptosis in

cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. *Cir Res* 2000; 86: 692-699.

28. Mackay K, Mochly-Rosen D. Involvement of a p38 mitogen-activated protein kinase phosphatase in protecting neonatal rat cardiac myocytes from ischemia. *J Mol Cell Cardiol* 2000; 32: 1585-1588.
29. Hoover HE, Thuerlauf DJ, Martindale KK, Glembotski CC. Alpha B-crystallin gene induction and phosphorylation by MKK6-activated p38. A potential role for alpha B-crystallin as a target of the p38 branch of the cardiac stress response. *J Biol Chem* 2000; 275:23825-23833.
30. Craig R, Larkin A, Mingo AM, Thuerlauf DJ, Andrews C, McDonough PM, Glembotski CC. p38 MAPK and NF-kappa B collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system. *J Biol Chem* 2000; 275: 23814-23824.
31. Seko Y, Takahashi N, Tobe K, Kadowaki T, Yazaki Y. Pulsatile stretch activates mitogen-activated protein kinase (MAPK) family members and focal adhesion kinase (p125(FAK)) in cultured rat cardiac myocytes. *Biochem Biophys Res Commun* 1999; 259: 8-14.
32. La Pointe MC, Isenovic E. Interleukin-1 beta regulation of inducible nitric oxide synthase and cyclooxygenase-2 involves the p42/44 and p38 MAPK

- signaling pathways in cardiac myocytes. *Hypertension* 1999; 33: 276-282.
33. Laderoute KR, Webster KA. Hypoxia/reoxygenation stimulates Jun kinase activity through redox signaling in cardiac myocytes. *Circ Res* 1997; 80:336-344.
  34. Yaglom J, O'Callaghan-Sunol C, Gabai V, Sherman MY. Inactivation of dual-specificity phosphatases is involved in the regulation of extracellular signal-regulated kinases by heat shock and hsp72. *Mol Cell Biol* 2003; 23: 3813-3824.
  35. Beere HM. Stressed to death: regulation of apoptotic signaling pathways by the heat shock proteins. *Sci STKE* 2001; 93: RE1.
  36. Bueno OF, De Windt LJ, Lim HW, Tymitz KM, Witt SA, Kimball TR, Molkenkin JD. The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response *in vitro* and *in vivo*. *Circ Res* 2001; 88: 88-96.
  37. Liu C, Shi Y, Han Z, Pan Y, Liu N, Han S, Chen Y, Lan M, Qiao T, Fan D. Suppression of the dual-specificity phosphatase MKP-1 enhances HIF-1 trans-activation and increases expression of EPO. *Biochem Biophys Res Commun* 2003; 312: 780-786.
  38. Stephan R, Abbas M, Isabelle P, Werner S. Stimulated initiation of mitogen-activated protein kinase phosphatase-1 (MKP-1) gene transcription involves the synergistic action of multiple cis-acting

- elements in the proximal promoter. *Biochem J* 2004; 378: 473-484.
39. Hayashi D, Kudoh S, Shiojima I, Zou Y, Harada K, Shimoyama M, Imai Y, Monzen K, Yamazaki T, Yazaki Y, Nagai R, Komuro I. Atrial natriuretic peptide inhibits cardiomyocyte hypertrophy through mitogen-activated protein kinase phosphatase-1. *Biochem Biophys Res Commun* 2004; 322: 310-319.
  40. Mosser DD, Caron AW, Bourget L, Denis-Larose C, Massie B. Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis. *Mol Cell Biol* 1997; 17:5317-5327.
  41. Gabai VL, Meriin AB, Mosser DD, Caron AW, Rits S, Shifrin VI, Sherman MY. Hsp70 prevents activation of stress kinases: a novel pathway of cellular thermotolerance. *J Biol Chem* 1997; 272: 18033-18037.
  42. Park HS, Lee JS, Huh SH, Seo JS, Choi EJ. Hsp72 functions as a natural inhibitory protein of c-Jun N-terminal kinase. *EMBO* 2001; 20: 446-456.
  43. Meriin AB, Yaglom JA, Gabai VL, Zon L, Ganiatsas S, Mosser DD, Zon L, Sherman MY. Protein-damaging stress activates c-Jun N-terminal kinase via inhibition of its dephosphorylation: a novel pathway controlled by Hsp72. *Mol Cell Biol* 1999; 19: 2547-2555.
  44. Coaxum SD, Martin JL, Mestral R. Overexpression of heat shock proteins



- differentially modulates protein kinase C expression in rat neonatal cardiomyocytes. *Cell Stress Chaperones* 2003; 8: 297-302.
45. Jamshidi Y, Zourlidou A, Carroll CJ, Sinclair J, Latchman DS. Signal-transduction pathways involved in the hypertrophic effect of hsp56 in neonatal cardiomyocytes. *J Mol Cell Cardiol* 2004; 36: 381-392.
  46. Kacimi R, Chentoufi J, Honbo N, Long CS, Karliner JS. Hypoxia differentially regulates stress proteins in cultured cardiomyocytes: role of the p38 stress-activated kinase signaling cascade, and relation to cytoprotection. *Cardiovasc Res* 2000; 46: 139-150.
  47. Spector DL, Goldman RD, Leinwand LA. *Cells, A Laboratory Manual*. Vol. 1: Cold Spring Harbor Laboratory Press: 1998. p.11.1-11.6.
  48. Wei C, Yan S, Ling L, Anthony R. Importance of FADD signaling in serum deprivation- and hypoxia-induced cardiomyocyte apoptosis. *J Biol Chem* 2002; 277: 31639-31645.
  49. Jaattela M. Heat shock proteins as cellular lifeguards. *Ann Med* 1999; 31: 261-271.
  50. Latchman DS. Heat shock proteins and cardiac protection. *Cardiovasc Res* 2001; 51: 637-646.
  51. Iwaki K, Chi SH, Dillmann WH, Mestril R. Induction of HSP70 in cultured rat neonatal cardiomyocytes by hypoxia and metabolic stress.

*Circulation* 1993; 87: 2023-2032.

52. Vives E, Richard JP, Rispal C, Lebleu B. TAT peptide internalization: seeking the mechanism of entry. *Curr Protein Pept Sci* 2003; 4: 125-132.
53. Garrido C, Schmitt E, Cande C, Vahsen N, Parcellier A, Kroemer G. HSP27 and HSP70: potentially oncogenic apoptosis inhibitors. *Cell Cycle* 2003; 2: 579-584.
54. Taylor RP, Starnes JW. Age, cell signalling and cardioprotection. *Acta Physiol Scand* 2003; 178: 107-116.
55. Saleh A, Srinivasula SM, Balkir L, Robbins PD, Alnemri ES. Negative regulation of the Apaf-1 apoptosome by Hsp70. *Nat Cell Biol* 2000; 2: 476-483.
56. Beere H M, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, Tailor P, Morimoto RI, Cohen G.M, Green DR. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. *Nat Cell Biol* 2000; 2: 469-475.
57. Franklin CC, Srikanth S, Kraft AS. Conditional expression of mitogenactivated protein kinase phosphatase-1, MKP-1, is cytoprotective against UV-induced apoptosis. *Proc Natl Acad Sci USA* 1998; 95: 3014-3019.
58. Guo YL, Kang B, Williamson JR. Inhibition of the expression of

mitogenactivated protein phosphatase-1 potentiates apoptosis induced by tumor necrosis factor-alpha in rat mesangial cells. *J Biol Chem* 1998; 273: 10362-10366.

59. Hermann DM, Hossmann KA, Mies G. Expression of c-jun, mitogen-activated protein kinase phosphatase-1, caspase-3 and glial fibrillary acidic protein following cortical cold injury in rats: relationship to metabolic disturbances and delayed cell death. *Neuroscience* 2004; 123: 371-379.
60. Craig R, Wagner M, McCardle T, Craig AG, Glembotski CC. The cytoprotective effects of the glycoprotein 130 receptor-coupled cytokine, cardiotrophin-1, require activation of NF-kappa B. *J Biol Chem* 2001; 276: 37621-37629.
61. Qiu J, Hu X, Nestic O, Grafe MR, Rassin DK, Wood TG, Perez-Polo JR. Effects of NF-kappaB oligonucleotide "decoys" on gene expression in P7 rat hippocampus after hypoxia/ischemia. *J Neurosci Res* 2004; 77: 108-118.
62. Huang Y, Li Z, Yang Z. Roles of ischemia and hypoxia and the molecular pathogenesis of post-burn cardiac shock. *Burns* 2003; 29: 828-833.
63. Zhou L, Tan A, Iasvovskaia S, Li J, Lin A, Hershenon MB. Ras and mitogen-activated protein kinase kinase-1 coregulate activator

protein-1- and nuclear factor-kappaB-mediated gene expression in airway epithelial cells. *Am J Respir Cell Mol Biol* 2003; 28: 762-769.

**ABSTRACT (KOREAN)**

< >

,

.

MAP kinas

가

70

(HSP70)

MKP-1

ERK

, MTT caspase-3 activity assay

MKP-1 가 ERK  
 70  
 가 , MKP-1  
 caspase-3 가 , ERK가  
 MKP-1  
 vanadate ERK ,  
 caspase-3  
 70  
 70 TAT  
 MKP-1  
 ERK  
 가 ,  
 MKP-1 ERK  
 70 MKP-1  
 : , 70, MKP-1, ERK,  
 ,